SCHEDULE: Avoro Capital Advisors Discloses 8.06% Stake in Centessa Pharma

Avoro Capital Advisors LLC and Behzad Aghazadeh have reported a passive 8.06% beneficial ownership stake in Centessa Pharmaceuticals plc, holding 10,808,080 American Depositary Shares.

Summary

• Avoro Capital Advisors LLC and its controlling person, Behzad Aghazadeh, have jointly filed a Schedule 13G, indicating beneficial ownership in Centessa Pharmaceuticals plc.
• The reporting persons beneficially own 10,808,080 American Depositary Shares (ADSs) of Centessa Pharmaceuticals plc.
• This ownership represents an 8.06% stake in the company's ordinary shares.
• The investment is for ordinary course of business purposes and is not intended to change or influence the control of the issuer.
• The percentage of class owned is calculated based on 134,073,436 ordinary shares outstanding as of August 1, 2025.
• Avoro Life Sciences Fund LLC has the right to receive dividends or proceeds from the sale of more than 5% of the ordinary shares.

Sentiment

Score: 7

Explanation: The disclosure of a significant 8.06% passive stake by a specialized life sciences investment firm like Avoro Capital Advisors is generally viewed positively, indicating investor confidence in Centessa Pharmaceuticals plc. While it's a passive investment, it suggests a belief in the company's long-term potential.

Positives

• A significant institutional investor, Avoro Capital Advisors, has taken an 8.06% stake in Centessa Pharmaceuticals, indicating confidence in the company's prospects.
• The investment is stated to be for ordinary course of business, suggesting a long-term, passive investment strategy.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain any forward-looking statements or guidance from Centessa Pharmaceuticals plc or the reporting persons regarding the company's future performance or strategic direction.

Management Comments

• This filing is a beneficial ownership report by an investor and does not include any direct quotes or paraphrased statements from Centessa Pharmaceuticals plc management.

Industry Context

In the biotechnology and pharmaceutical industry, institutional investments like this Schedule 13G filing by Avoro Capital Advisors can signal investor confidence in a company's drug pipeline, research capabilities, or market potential. Such filings are common for publicly traded companies, especially those in growth-oriented sectors like biotech, where significant capital is often required for R&D and clinical trials. A substantial stake by a specialized life sciences fund like Avoro Life Sciences Fund LLC suggests a belief in Centessa Pharmaceuticals' long-term value proposition.

Comparison to Industry Standards

• This filing reports a beneficial ownership stake and does not provide financial or operational results that can be directly compared to industry benchmarks or specific comparable companies. The significance lies in the identity of the investor and the size of the stake, which is a common practice in institutional investment across various industries.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor taking a passive stake could be seen as a positive signal, potentially boosting investor confidence and share price.
• Company Management: May view this as validation of their strategy and potential long-term support from a major shareholder.

Next Steps

• The filing itself does not outline any specific future actions, events, or milestones for Centessa Pharmaceuticals plc or the reporting persons beyond the ongoing passive investment.

Key Dates

Recommendation

While the disclosure of a significant passive stake by a reputable life sciences investor like Avoro Capital Advisors is a positive signal, a Schedule 13G filing primarily reports a historical ownership position. It does not provide new operational or financial data from Centessa Pharmaceuticals plc that would warrant a 'buy' or 'sell' recommendation based solely on this document. The investment indicates confidence, but further analysis of the company's fundamentals, pipeline, and market conditions would be necessary for a stronger recommendation. Therefore, a 'hold' recommendation is appropriate, acknowledging the positive investor interest without overstating the immediate impact on the company's intrinsic value.

Keywords

Centessa Pharmaceuticals, Avoro Capital Advisors, Behzad Aghazadeh, Schedule 13G, Beneficial Ownership, CNTA, Biotechnology, Pharmaceuticals, Investment, ADSs